Stelara vs Remicade for Crohn's: mechanism, healing, safety, and dosing compared.

How Stelara and Humira compare in Crohn's, with SEAVUE trial data.

What Crohn's patients should know when weighing Humira vs Remicade.

Entyvio vs Remicade for Crohn's: gut-selective vs anti-TNF infusion options.

Entyvio vs Humira for Crohn's: gut-selective vs systemic, compared.

What to do when your Crohn's biologic stops working.

What actually happens when you're hospitalized for Crohn's.

Learn what your Crohn's lab results actually mean.

How to stay hydrated when Crohn's makes it harder.

What to know about short bowel syndrome after Crohn's surgery.

Why Crohn's raises your risk for stones and how to prevent them.

What your Crohn's colonoscopy report actually means.

A sick-day manual for immunosuppressed Crohn's patients.

Is it a flare or a bug? Here's how to tell.

How Crohn's affects your body image and what helps.

Why Crohn's makes you exhausted and what to do about it.

How Crohn's affects your mouth and what to do about it.

Colonoscopy prep tips designed for Crohn's patients.

What the evidence actually says about cannabis for Crohn's.

Why Crohn's patients are more vulnerable to C. diff.

What clinical trials say about tracking symptoms for Crohn's and colitis.

Practical, severity-based guidance for staying active during an IBD flare.

Your guide to ADA protections, FMLA leave, and disability benefits with Crohn's.

Exactly what to log in your Crohn's symptom diary to make every GI appointment count.

A stage-by-stage guide to eating through a Crohn's flare, from day one to recovery.

A practical crisis guide for managing Crohn's flares with confidence.

Everything you need to know about Crohn's after a new diagnosis.

Why Crohn's develops and what you can actually control.

Which vaccines are safe on your Crohn's meds, and which ones to avoid.

Your Crohn's type shapes your treatment. Here's how to decode your diagnosis.

Plan every phase of travel with Crohn's, from medication logistics to restroom access.

What the research actually shows for every Crohn's supplement and alternative treatment.

How Crohn's disrupts your sleep, and what actually works to break the cycle.

Your child's actual UC risk, by the numbers, and what to watch for.

The complete practical toolkit for daily Crohn's logistics in one guide.

What probiotics actually work for Crohn's? Here's what the clinical trials show.

Your stage-by-stage guide to a healthy pregnancy with Crohn's disease.

What steroids actually feel like, how to taper safely, and when to push for biologics.

What each perianal Crohn's symptom means and what to do about it.

Every financial resource for Crohn's treatment in one guide.

Know which vitamins to test based on your Crohn's disease location and how to replenish them.

Your family risk numbers, the genetics behind them, and what to watch for in kids.

What Crohn's patients need to know about azathioprine, 6-MP, and methotrexate.

Why feeling fine isn't enough, and what to track to keep Crohn's in check.

Practical scripts for explaining Crohn's to people who don't understand.

Understand every test in the Crohn's diagnostic workup and what your results mean.

How to find the right specialist and build a care team for Crohn's.

Practical exercise guidance for every stage of Crohn's disease.

The early warning signs of Crohn's that most symptom lists miss.

Practical guidance from first-date disclosure to long-term intimacy with Crohn's.

Understand how Crohn's, UC, IBS, and celiac differ and what it means for treatment.

Which foods actually worsen Crohn's, and which just cause symptoms?

What's real and what's hype in Crohn's research right now.

Why Crohn's causes fatigue, brain fog, and symptoms you'd never blame on your gut.

What your Crohn's symptoms reveal about your disease location and when to call your GI.

Every surgical option for Crohn's, plus the recurrence plan that matters most.

Navigate the Crohn's support ecosystem with confidence.

Why women wait 3x longer for a Crohn's diagnosis, and what to do about it.

Every surgical option for Crohn's, from decision to recovery and beyond.

What the research actually says about living with Crohn's long-term.

What parents need to know about pediatric Crohn's, from dietary therapy to school plans.

What changes when Crohn's is diagnosed after 60, and how to manage it safely.

Which Crohn's diet actually has evidence? A side-by-side comparison of every approach.

Know which Crohn's complications need the ER and which need your next GI appointment.

What Crohn's does outside your gut, and which symptoms need urgent attention.

College, career, and insurance guidance for young adults with Crohn's.

Why Crohn's affects your mind and what actually helps.

What Crohn's patients need to know about cancer risk and when to start screening.

Which foods are safe with Crohn's? A practical guide for every stage of disease.

Compare every biologic class for Crohn's with real trial data and switching guidance.

How alcohol, smoking, vaping, and cannabis really affect your Crohn's disease.

Tysabri and Tremfya represent very different positions in the Crohn's biologic landscape. Tremfya (guselkumab) is an IL-23 p19-selective biologic approved for Crohn's in March 2025 based on GALAXI-2, GALAXI-3, and GRAVITI. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk and typically reserved for refractory cases. This guide walks through the tysabri vs tremfya crohn's comparison.

Tysabri and Stelara take very different mechanistic approaches to moderate-to-severe Crohn's disease. Stelara (ustekinumab) is an IL-12/23 biologic that is widely prescribed for Crohn's. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk. Both drugs are often considered in patients with complex treatment histories who have failed anti-TNFs or other options. This guide walks through the tysabri vs stelara crohn's comparison.

Tysabri and Skyrizi represent two different generations and positions in the Crohn's biologic landscape. Skyrizi (risankizumab) is an IL-23 p19-selective biologic approved for Crohn's in June 2022 based on ADVANCE, MOTIVATE, and FORTIFY, increasingly prescribed as a first-line or second-line option. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk and typically reserved for refractory cases. This guide walks through the tysabri vs skyrizi crohn's comparison.

Tysabri and Remicade are two IV biologics for moderate-to-severe Crohn's disease that take very different mechanistic approaches and differ sharply in how they are prescribed, monitored, and accessed. Remicade (infliximab) is a widely prescribed first-line IV anti-TNF biologic. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to risk of progressive multifocal leukoencephalopathy (PML). This guide walks through the tysabri vs remicade crohn's comparison.

Tysabri and Omvoh represent very different positions in the Crohn's biologic landscape. Omvoh (mirikizumab) is the newest IL-23 p19-selective biologic for Crohn's, approved in January 2025 based on VIVID-1. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk and typically reserved for refractory cases. This guide walks through the tysabri vs omvoh crohn's comparison.

Tysabri and Humira take very different mechanistic approaches to moderate-to-severe Crohn's disease, and they differ sharply in how they are prescribed, monitored, and accessed. Humira (adalimumab) is a subcutaneous anti-TNF biologic that is widely prescribed as a first-line biologic for Crohn's. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to risk of progressive multifocal leukoencephalopathy (PML). This guide walks through the tysabri vs humira crohn's comparison.

Tysabri and Entyvio both target integrins in the pathway that drives immune cell trafficking in Crohn's disease, but they differ in which integrin subunit they block, and that difference creates profoundly different safety profiles. Entyvio (vedolizumab) is gut-selective and has a favorable safety record. Tysabri (natalizumab) blocks a broader integrin target that includes trafficking to the brain, creating a risk of progressive multifocal leukoencephalopathy (PML) that requires the TOUCH program to manage. This guide walks through the tysabri vs entyvio crohn's comparison.

Tysabri and Cimzia are both less commonly prescribed biologics for moderate-to-severe Crohn's disease, each with specific niches in the treatment landscape. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic with a distinctive structure that makes it notable for pregnancy considerations. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk. This guide walks through the tysabri vs cimzia crohn's comparison.

Tremfya and Stelara are both Johnson & Johnson biologics for moderate-to-severe Crohn's disease, and they present a rare scenario where a manufacturer's newer drug is being compared head-to-head with its predecessor. Stelara has been the workhorse IL-12/23 biologic in IBD since its Crohn's approval in 2016. Tremfya is a newer p19-selective IL-23 biologic that J&J brought to IBD markets starting in 2024. The GALAXI 2 and GALAXI 3 trials directly compared these two drugs in Crohn's, and the results favor Tremfya on endoscopic endpoints. This guide walks through what Crohn's patients need to know when weighing the tremfya vs stelara crohn's decision.

Tremfya and Remicade are two of the biologics Crohn's patients commonly consider when Remicade has lost effect or when starting a first biologic. Remicade has been the anti-TNF standard for more than two decades. Tremfya is a newer IL-23 p19-selective biologic that gained Crohn's approval in 2024 based on the GALAXI trial program. The drugs take very different mechanistic approaches and offer different administration options, which shapes the decision for many Crohn's patients. This guide walks through the tremfya vs remicade crohn's comparison.

Tremfya and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe Crohn's disease, each newly approved for the indication. Tremfya gained Crohn's approval in March 2025 based on GALAXI-2 and GALAXI-3, with the GRAVITI trial supporting a fully subcutaneous induction option. Omvoh gained Crohn's approval in January 2025 based on VIVID-1. Patients comparing these two within-class options often weigh administration flexibility and active-comparator trial design. This guide walks through the tremfya vs omvoh crohn's comparison.

Tremfya and Humira represent two different eras in Crohn's biologic therapy. Humira is a fully human anti-TNF biologic that has been a Crohn's staple since 2007. Tremfya is an IL-23 p19-selective biologic that gained Crohn's approval in 2024 and uniquely offers both subcutaneous and intravenous induction pathways. Patients comparing these drugs often weigh mechanism, administration flexibility, and the strength of the available trial evidence. This guide walks through the tremfya vs humira crohn's decision.

Tremfya and Entyvio are two non-anti-TNF biologics for moderate-to-severe Crohn's disease, and patients often compare them when prioritizing safety or looking for alternatives to systemic TNF blockade. Tremfya is an IL-23 p19-selective biologic with strong endoscopic data from the GALAXI and GRAVITI trials. Entyvio is gut-selective and acts almost exclusively on the intestines. Both offer meaningful safety advantages over anti-TNFs, but they work through very different mechanisms. This guide walks through the tremfya vs entyvio crohn's comparison.

Skyrizi and Tremfya are both IL-23 p19-selective biologics for moderate-to-severe Crohn's disease, made by competing manufacturers (AbbVie and Johnson & Johnson). Both drugs belong to the same mechanism class and target the same cytokine subunit, so the skyrizi vs tremfya crohn's comparison often comes down to trial data, administration options, and maintenance convenience. This guide walks through the key differences to help you discuss the decision with your GI.

Skyrizi and Stelara are two interleukin-pathway biologics for moderate-to-severe Crohn's disease, and until recently the choice between them was largely mechanistic speculation. That changed with the SEQUENCE trial, a rare head-to-head randomized study that directly compared risankizumab (Skyrizi) with ustekinumab (Stelara) in Crohn's patients who had failed an anti-TNF. The results have reshaped how many gastroenterologists think about IL-23 targeting and have moved Skyrizi toward the front of the line for biologic-experienced Crohn's disease. This guide walks through the SEQUENCE findings and the practical decisions patients need to make with their GI.

Skyrizi and Remicade represent two very different eras of Crohn's biologic therapy. Remicade (infliximab) has been the anti-TNF workhorse since its approval in the late 1990s. Skyrizi (risankizumab) is a newer IL-23 p19-selective biologic that gained Crohn's approval in 2022 and has quickly gained market share. Patients often compare these drugs when starting biologic therapy for the first time or when weighing alternatives after Remicade has lost effect. This guide walks through the evidence for the skyrizi vs remicade crohn's decision.

Skyrizi and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe Crohn's disease. Skyrizi gained Crohn's approval in June 2022 based on the ADVANCE, MOTIVATE, and FORTIFY trials. Omvoh gained Crohn's approval in January 2025 based on VIVID-1. Patients comparing these two within-class options often weigh maintenance dosing, trial design, and GI familiarity with each drug. This guide walks through the skyrizi vs omvoh crohn's comparison.

Skyrizi and Humira are both AbbVie biologics for moderate-to-severe Crohn's disease, and they represent very different mechanisms. Humira is the long-established anti-TNF standard with more than two decades of use in IBD. Skyrizi is a newer IL-23 p19-selective biologic that gained Crohn's approval in 2022 and has quickly become a prescribing favorite. For patients weighing a first-line biologic, the skyrizi vs humira crohn's decision often comes down to mechanism, administration preferences, and data from anti-TNF experienced cohorts. This guide walks through the evidence Crohn's patients need to discuss with their gastroenterologist.

Skyrizi and Entyvio are two non-anti-TNF biologics for moderate-to-severe Crohn's disease, and they take very different approaches to quieting gut inflammation. Skyrizi is an IL-23 p19-selective biologic that acts on the immune system more broadly while still avoiding TNF blockade. Entyvio is gut-selective and acts almost exclusively on the intestines. Both are increasingly common choices for patients who have failed an anti-TNF or want to avoid systemic immunosuppression from the start. This guide walks through the evidence Crohn's patients need for the skyrizi vs entyvio crohn's decision.

Omvoh and Stelara are two IL-23 pathway biologics for moderate-to-severe Crohn's disease, but they target the pathway at different points. Stelara blocks both IL-12 and IL-23 through the shared p40 subunit. Omvoh selectively blocks only IL-23 through its p19 subunit. The scientific rationale behind p19 selectivity is that IL-23 is the dominant driver of Crohn's inflammation while IL-12 plays broader immune roles that may not need blocking. Omvoh's VIVID-1 trial directly compared mirikizumab with ustekinumab as an active comparator, giving patients meaningful head-to-head data. This guide walks through the omvoh vs stelara crohn's decision.

Omvoh and Remicade represent two very different generations of Crohn's biologic therapy. Remicade has been the anti-TNF standard for Crohn's since the late 1990s. Omvoh is the newest IL-23 p19-selective biologic for Crohn's, gaining FDA approval in January 2025 based on the VIVID-1 trial. Patients commonly compare these drugs when choosing a first-line biologic or when weighing alternatives after Remicade has lost effect. This guide walks through the omvoh vs remicade crohn's comparison.

Omvoh and Humira are two biologics for moderate-to-severe Crohn's disease that work through very different mechanisms. Humira is a fully human anti-TNF biologic with more than two decades of experience in IBD. Omvoh is an IL-23 p19-selective biologic approved for Crohn's in January 2025 based on the VIVID-1 trial. Patients weighing these two drugs are often choosing between an established anti-TNF and a newer IL-23 option. This guide walks through the omvoh vs humira crohn's decision.

Omvoh and Entyvio are two non-anti-TNF biologics for moderate-to-severe Crohn's disease, each offering meaningful safety advantages over anti-TNFs through very different mechanisms. Omvoh is an IL-23 p19-selective biologic approved for Crohn's in January 2025 based on VIVID-1. Entyvio is gut-selective and has been a Crohn's treatment option since 2014. Patients comparing these drugs often prioritize long-term safety or are weighing alternatives after anti-TNF failure. This guide walks through the omvoh vs entyvio crohn's decision.

Entyvio and Stelara are two of the most common biologics prescribed when an anti-TNF like Humira or Remicade stops working for Crohn's disease. Both are alternatives to TNF blockade, but they take very different mechanistic paths to quiet gut inflammation. Entyvio is gut-selective. Stelara targets a cytokine pathway that operates throughout the body but is especially active in the gut. For patients weighing a second-line choice, the decision often hinges on infection risk, onset of action, and long-term safety. This guide walks through the evidence patients need to make an informed entyvio vs stelara crohn's decision with their gastroenterologist.

Cimzia and Tremfya represent two very different generations of biologic therapy for moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic that has been a Crohn's option since 2008. Tremfya (guselkumab) is an IL-23 p19-selective biologic that gained Crohn's approval in March 2025 based on GALAXI-2, GALAXI-3, and GRAVITI. Patients comparing these drugs weigh established anti-TNF mechanism against a newer IL-23 class with distinctive induction flexibility. This guide walks through the cimzia vs tremfya crohn's comparison.

Cimzia and Stelara are two subcutaneous biologics for moderate-to-severe Crohn's disease that work through fundamentally different mechanisms. Cimzia (certolizumab pegol) is an anti-TNF biologic. Stelara (ustekinumab) is an IL-12/23 inhibitor. Patients comparing these drugs often weigh established TNF-alpha blockade against the IL-12/23 pathway, particularly when considering first-line therapy or switching after anti-TNF failure. This guide walks through the cimzia vs stelara crohn's decision.

Cimzia and Skyrizi represent two different generations of biologic therapy for moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic that has been a Crohn's option since 2008. Skyrizi (risankizumab) is an IL-23 p19-selective biologic approved for Crohn's in June 2022 based on the ADVANCE, MOTIVATE, and FORTIFY trials. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with strong efficacy and safety data. This guide walks through the cimzia vs skyrizi crohn's comparison.

Cimzia and Remicade are two anti-TNF biologics for moderate-to-severe Crohn's disease, but they take different administration routes. Cimzia (certolizumab pegol) is a subcutaneous injection. Remicade (infliximab) is an intravenous infusion. Both block TNF-alpha, but the administration difference and Cimzia's unique Fab structure shape the practical comparison. This guide walks through the cimzia vs remicade crohn's decision.

Cimzia and Omvoh represent two very different generations of biologic therapy for moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic that has been a Crohn's option since 2008. Omvoh (mirikizumab) is a newer IL-23 p19-selective biologic that gained Crohn's approval in January 2025 based on VIVID-1. Patients comparing these drugs weigh established anti-TNF mechanism against a newer IL-23 class. This guide walks through the cimzia vs omvoh crohn's comparison.

Cimzia and Humira are two subcutaneous anti-TNF biologics for moderate-to-severe Crohn's disease. Both block TNF-alpha, but they differ in molecular structure in ways that can matter for specific patient populations, particularly those considering pregnancy. Cimzia (certolizumab pegol) is a PEGylated antibody fragment without an Fc region, while Humira (adalimumab) is a full IgG antibody. This guide walks through the cimzia vs humira crohn's comparison.

Cimzia and Entyvio take very different mechanistic approaches to moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic. Entyvio (vedolizumab) is a gut-selective biologic. Patients comparing these drugs often weigh a systemic anti-TNF approach against a gut-targeted strategy with a favorable systemic safety profile. This guide walks through the cimzia vs entyvio crohn's comparison.